B. Koul et al., HEARTMATE LEFT-VENTRICULAR ASSIST DEVICE AS BRIDGE TO HEART-TRANSPLANTATION, The Annals of thoracic surgery, 65(6), 1998, pp. 1625-1630
Citations number
15
Categorie Soggetti
Surgery,"Cardiac & Cardiovascular System","Respiratory System
Background. Because of the limited supply of donor hearts, prospective
recipients continue to die while on the waiting list for heart transp
lantation. Use of longterm mechanical circulatory support devices as a
bridge to transplantation may reduce this mortality. However, with th
e present state of technology, continued clinical evaluation of the va
rious long-term, mechanical circulatory support devices available is m
andatory. Methods. Sixteen patients were bridged with the HeartMate le
ft ventricular assist device (LVAD) to heart transplantation for New Y
ork Heart Association functional class IV cardiac failure. Twelve pneu
matic and six electric devices were used. The mean cardiac index and t
he mean pulmonary vascular resistance of the patient cohort were 1.71.
min(-1).m(-2) and 3.1 Wood units, respectively. Results. The mean LVAD
support time per transplanted patient was 237 days, with a cumulative
LVAD support time of about 7.2 years. Bleeding was the main operative
and postoperative complication. Two patients suffered from neurologic
complications and there were two major incidents of device malfunctio
n. Twelve patients (75%) now have received a transplant, 3 (19%) ire a
waiting a transplant, and in 1 patient (6%), the device was explanted
after spontaneous left ventricular recovery. Eleven of the 12 patients
who received a transplant are alive and doing well. The HeartMate LVA
D gave adequate circulatory support over extended periods of time and
reversed the vital organ dysfunction. Since the start of the LVAD prog
ram, only 1 patient has died on our heart transplantation waiting list
, compared to nine deaths in the 2 preceding years. Conclusions. The H
eartMate LVAD bridge to heart transplantation can be performed with lo
w post-LVAD implantation and posttransplantation mortality and offers
1- and 2-year posttransplantation actuarial survival rates comparable
to those for nonbridged heart transplant recipients. (C) 1998 by The S
ociety of Thoracic Surgeons.